'Hazard ratio' presentation slideshows

Survival Analysis in SAS

1.88k views • 100 slides

UPDATE EN CARDIOLOGIA 2008

1.1k views • 99 slides

Health Literacy Starter Kit: Basic Information and Resources for the Newcomer

Health Literacy Starter Kit: Basic Information and Resources for the Newcomer. Paul D. Smith, MD Julie McKinney UW Department of Family Medicine World Education Paul.Smith@fammed.wisc.edu julie_mcKinney@worlded.org. Topics today.

936 views • 74 slides

NOTE FOR HEALTHCARE PROFESSIONAL

NOTE FOR HEALTHCARE PROFESSIONAL. This presentation has been provided to you upon request. If presenting this to other healthcare professionals, GSK advises that you use the presentation in full to ensure a fair balance of information, both efficacy and safety.

843 views • 70 slides

Personalized Therapy in Colorectal Cancers

Personalized Therapy in Colorectal Cancers. J. Randolph Hecht, MD Professor of Clinical Medicine Director, UCLA GI Oncology Program David Geffen School of Medicine at UCLA. What Does Personalized Therapy Mean?. Right Treatment Right Patients. Biomarker.

878 views • 63 slides

Developments in the Treatment of Multiple Myeloma Kenneth C. Anderson, M.D.

Developments in the Treatment of Multiple Myeloma Kenneth C. Anderson, M.D. Kraft Family Professor of Medicine Harvard Medical School Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute. Conflict of Interest: Kenneth C. Anderson, M.D.

773 views • 56 slides

Journal Club

Journal Club. Lei Zhang PGY 3 7/16/09. Case. 55 y.o. F, PMH HTN, DM, TIA, and diverticulosis Had multitple diverticulitis, lower GIB in the past Scheduled to have elective colon resection in 2 wks Presented to the office for pre-op clearance Denied CP, SOB, swelling. Case.

649 views • 55 slides

Use and Overuse: How the Marketing of One Drug May Have Harmed the Patients It Was Supposed to Help

Use and Overuse: How the Marketing of One Drug May Have Harmed the Patients It Was Supposed to Help. Jamie Johnston, MD University of Pittsburgh School of Medicine. Disclosures. Stockholder Pfizer and Merck (Both < $10K) Before 2005 Talks for Pfizer, Merck, Genzyme and one for Amgen

562 views • 46 slides

Global Research for Global Action

515 views • 45 slides

843 views • 35 slides

Background

Maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer Phase 3 CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).

588 views • 31 slides

When Using DOPPS Slides

When Using DOPPS Slides. DOPPS Slide Use Guidelines. Physical exercise among participants in the DOPPS: correlates and associated outcomes. Introduction. DOPPS Background (1). DOPPS Background (2). Methods (1). Methods (2). Methods (3). Methods (4).

378 views • 29 slides

Vaccinations and other health maintenance issues for the patient on immune suppressive therapies

396 views • 28 slides

Efficacy and safety of fondaparinux in elderly patients with STEMI results of the OASIS 6 trial

Efficacy and Safety of Fondaparinux in Elderly Patients With ST-Segment Elevation Myocardial Infarction: Data From the OASIS 6 Trial Ron J.G. Peters, MD Cardiologist Department of Cardiology University of Amsterdam Amsterdam, Netherlands.

446 views • 22 slides

Ismahen BEN YAACOUB-KZADRI, Sana HARGUEM,

Impact of M yocardial T hickness on Viability assessment on L ate Gadolinium E nhancement S equences . Ismahen BEN YAACOUB-KZADRI, Sana HARGUEM, Rym BENNACEUR, Imen GANZOUI, Aicha BEN MILED, Najla MNIF. Radiology department, Charles Nicolle Hospital, Tunis - TUNISIA.

305 views • 18 slides

CV Risk and Lipids in Asia: Epidemiology

CV Risk and Lipids in Asia: Epidemiology. The Burden of CVD in Asia: Stroke Deaths by Country, 2002. WHO CVD Atlas. 2002. WHO Stroke Atlas. 2002. The Burden of CVD in Asia: CHD Deaths by Country, 2002. WHO CVD Atlas. 2002. WHO Stroke Atlas. 2002.

240 views • 17 slides

Landmark Statin Trials Across the Spectrum of Risk: Secondary Stroke Prevention

Landmark Statin Trials Across the Spectrum of Risk: Secondary Stroke Prevention . Simvastatin in Patients With Prior Cerebrovascular Disease: HPS. 29.8. 24.7*. Simvastatin. Placebo. 10.3. 10.4. (N=488). N=406. N=169. N=170. Major Vasular Events. Stroke. *29% RRR, p =0.001

276 views • 12 slides

242 views • 11 slides

Physical Counterpressure Maneuver (PC) Trial

Physical Counterpressure Maneuver (PC) Trial. Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. N. van Dijk. PC-Trial: Background.

1.07k views • 9 slides

0.1 1 10

0.1 1 10. Hazard ratio (95% CI) for all-cause mortality through Day 180.

113 views • 1 slides